Botulinum neurotoxin A and an engineered derivate targeted secretion inhibitor (TSI) A enter cells via different vesicular compartments

References

• Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010;79:591–617
   PubMed Web of Science ®Google Scholar
• Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 2014;12:535–49
   PubMed Web of Science ®Google Scholar
• Foster KA. Overview and history of botulinum neurotoxin clinical exploitation. In: Foster KA, ed. Current topics in neurotoxicity. 5: Clinical applications of botulinum neurotoxin. New York: Springer; 2014:1–5
   Google Scholar
• Verderio C, Rossetto O, Grumelli C, et al. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep 2006;7:995–9
   PubMed Web of Science ®Google Scholar
• Colasante C, Rossetto O, Morbiato L, et al. Botulinum neurotoxin type A is internalised and translocated form small synaptic vesicles at the neuromuscular junction. Mol Neurobiol 2013;48:120–7
   PubMed Web of Science ®Google Scholar
• Antonucci F, Rossi C, Gianfranceschi l, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008;28:3689–96
   PubMed Web of Science ®Google Scholar
• Marinelli S, Vacca V, Ricordy R, et al. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One 2012;7:10, e47977
   Web of Science ®Google Scholar
• Restani L, Novelli E, Bottari D, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 2012;13:1083–9
   PubMed Web of Science ®Google Scholar
• Marchand-Pauvert V, Aymard C, Giboin L-S, et al. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol 2013;591:1017–29
   PubMed Web of Science ®Google Scholar
• Restani L, Giribaldi F, Manich M, et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLOS Pathogens 2012;8:12, e1003087
   Web of Science ®Google Scholar
• Meng J, Wang J, Lawrence GW, et al. Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons. FASEB J 2013;27:3167–80
   PubMed Web of Science ®Google Scholar
• Masuyer G, Chaddock JA, Foster KA, et al. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol 2014;54:27–51
   Google Scholar
• Chaddock JA. Future developments: engineering the neurotoxin. In Foster KA, ed. Current Topics in neurotoxicity. 5: Clinical applications of botulinum neurotoxin. New York: Springer; 2014:177–90
   Google Scholar
• Chaddock JA, Purkiss JR, Duggan MJ, et al. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 200;18:147–55
   Google Scholar
• Chaddock JA, Purkiss JR, Friis LM, et al. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect Immun 2000;68:2587–93
   PubMed Web of Science ®Google Scholar
• Foster KA, Adams EJ, Durose L, et al. Re-engineering the target specificity of clostridial neurotoxins – a route to novel therapeutics. Neurotox Res 2006;9:101–7
   PubMed Web of Science ®Google Scholar
• Somm E, Bonnet N, Martinez A, et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Investig 2012;9:3295–306
   Web of Science ®Google Scholar
• Somm E, Bonnet N, Zizzari P, et al. Comparative inhibition of the GH/IGF-1 axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology 2013;154:4237–48
   PubMed Web of Science ®Google Scholar
• Leggett J, Harper E, Waite E, et al. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats. Neuroendocrinology 2013;154:3305–18
   Google Scholar
• Garcia EA, Trivellin G, Aflorei ED, et al. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly? J Clin Endocrinol Metab 2013;98:12, e1919–26
   Web of Science ®Google Scholar
• Masuyer G, Thiyagarajan N, James PL, et al. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. Biochem Biophys Res Commun 2009;381:50–3
   PubMed Web of Science ®Google Scholar
• Masuyer G, Beard M, Cadd VA, et al. Structure and activity of a functional derivative of clostridium neurotoxin B. J Struct Biol 2011;174:52–7
   PubMed Web of Science ®Google Scholar
• Concepcion J, Witte K, Wartchow C, et al. Label-free detection of biomolecular interactions using biolayer interferometry for kinetic characterization. Comb Chem High Throughput Screen 2009;12:791–800
   PubMed Web of Science ®Google Scholar
• Pellet S, Tepp WH, Clancy CM, et al. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett 2007;581:4803–8
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Bereczky B, Yohioka K, et al. A novel role of Rho-kinase in the regulation of ligand-induced phosphorylated EGFR endocytosis via the early/late endocytic pathway in human fibrosarcoma cells. J Mol Hist 2011;42:427–42
   PubMed Web of Science ®Google Scholar
• Fernandez-Salas E, Wang J, Molina Y, et al. Botulinum neurotoxin serotype A specific-cell-based potency assay to replace the mouse bioassay. PLoS One 2012;7:11, e49516
   Web of Science ®Google Scholar
• Marini P, MacLeod RAF, Treuner C, et al. SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation. Cancer Genet Cytogenet 1999;112:161–4
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith TJ, Wright P, et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2 and A3. Vaccine 2009;27:4490–7
   PubMed Web of Science ®Google Scholar
• Band PA, Blais S, Neubert TA, et al. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Exp Purif 2010;71:62–73
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Stanker LH, et al. Neuronal targeting, internalisation and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. BBRC 2009;405:673–7
   Web of Science ®Google Scholar
• Baskaran P, Lehman TE, Topchiy E, et al. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions. Toxicon 2013;72:71–80
   PubMed Web of Science ®Google Scholar
• Vazquez-Cintron EJ, Vakulenko M, Band PA, et al. Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm. PLoS One 2014;9:1, e85517
   Web of Science ®Google Scholar
• Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16–21
   PubMed Web of Science ®Google Scholar
• Ruthel G, Burnett JC, Nuss JE, et al. Post-intoxication inhibitor of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins 2011;3:207–17
   PubMed Web of Science ®Google Scholar
• Harper CB, Martin S, Nguyen TH, et al. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem 2011;286:35966–76
   PubMed Web of Science ®Google Scholar
• Sigismund S, Argenzio E, Tosoni D, et al. Clathrin-mediated internalization is essential for sustained EGFR signalling but dispensable for degradation. Dev Cell 2008;15:209–19
   PubMed Web of Science ®Google Scholar
• Henriksen L, Grandal MV, Knudsen SLJ, et al. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One 2013;8:3, e58148
   Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signalling and cancer. TiCB 2014;4:26–34
   Web of Science ®Google Scholar
• Fu A, Tang R, Hardie J, et al. Promises and pitfalls of intracellular delivery of proteins. Bioconjugate Chem 2014;25:1602–8
   PubMed Web of Science ®Google Scholar
• Fischer A, Mushrush DJ, Lacy DB, et al. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathogens 2008;4:12, e1000245
   Web of Science ®Google Scholar
• Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-z: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 1991;2:599–612
   PubMedGoogle Scholar
• Saheki Y, De Camilli P. Synaptic vesicle endocytosis. Cold Spring Harb Perspect Biol 2012;4:a005645
   Web of Science ®Google Scholar